Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 plus pembrolizumab versus placebo plus pembrolizumab in first-line advanced KRAS G12C-mutant PD-L1-high NSCLC
NL-OMON59616Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-1084 plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Nov 2024; status: recruiting.
02
Drugs
calderasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59616.